November 19, 2018 08:23 AM ESTUpdated 08:39 AM

Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers

Amber Tong

Alphamab Oncology believes it has what it takes to stand out from the deluge of checkpoint inhibitors currently in development — not just in China but …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers

Amber Tong

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

Seek­ing an edge in the glob­al I/O race, Al­pham­ab On­col­o­gy loads up $100M-plus from mar­quee back­ers

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers